North American research underway to study SIMBA capsules
Lallemand Health Solutions and Nimble Science have announced the start of the first North American study of Nimble’s Small Intestine Microbiome Aspiration (SIMBA) Capsule, which passively samples the small intestine and transits the gastrointestinal tract.
SIMBA capsule. Image courtesy of Lallemand Health Solutions
Lallemand Health Solutions (Mirabel, Canada), and Nimble Science have announced the start of the first North American study of Nimble’s Small Intestine Microbiome Aspiration (SIMBA) Capsule, led by Dr. Christopher N. Andrews of the Division of Gastroenterology at the University of Calgary. The SIMBA ingestible capsule passively samples the small intestine and autonomously transits the gastrointestinal tract. The study began on December 22, 2020 with 20 participants and is estimated to be complete in March of 2021. The study is being conducted under Investigational Testing authorization from Health Canada (#318739) and University of Calgary Conjoint Research Ethics Board (REB20-1211).
“This particular capsule can be used to provide a novel solution for research of the gut microbiota, investigating various health conditions etiology, impact of interventions specifically within the small intestine and new biomarker identification, hence leading to advances in personalized medicine and nutrition. Lallemand Health Solutions is proud to support this innovative non-invasive technology to improve the understanding of probiotic intervention”, said Sara Caballero, clinical research specialist at the Rosell Institute for Microbiome and probiotics, by Lallemand, in a press release.
